Moderna Falls After Reports Highlight Potential Patent Issues

Aug. 11, 2020, 4:30 PM

Moderna fell as much as 7% after Reuters and Axios earlier highlighted language in a 10-Q filing from last week where the company discussed patent risks to its Covid vaccine. Arbutus Biopharma, which recently won a patent challenge against MRNA, rose as much as 8.5%.

  • Moderna said in Aug. 6 10-Q filing that “we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions, including mRNA-1273”

To contact the reporter on this story:
Joshua Fineman in ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.